Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu
Trial record 1 of 1 for:    VOCAL | Ovary Cancer
Previous Study | Return to List | Next Study

Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy (VOCAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03837327
Recruitment Status : Recruiting
First Posted : February 12, 2019
Last Update Posted : June 28, 2022
Information provided by (Responsible Party):
Venn Biosciences Corporation

Brief Summary:

Venn Biosciences Corporation ("InterVenn") has developed a liquid biopsy that is capable of distinguishing benign from malignant masses in women presenting with adnexal (pelvic) masses, through a simple blood test. The underlying technology combines mass spectrometry and artificial intelligence/machine learning to analyze tumor-associated changes in circulating glycoproteins.

The purpose of this study is to prospectively collect de-identified biological samples and data from women with a known pelvic mass, in order to validate ovarian cancer specific glycoproteomic signatures in the blood based on histologically confirmed malignancy status of the mass.

Condition or disease
Adnexal Mass Ovarian Cancer Pelvic Mass

Detailed Description:
This is a prospective, international, multi-center, observational study with a goal of collecting de-identified samples and data from 1,200 women with a known pelvic mass. Participants will consent to baseline and follow-up data and biospecimen collections.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1200 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy (VOCAL)
Actual Study Start Date : April 16, 2019
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2024

Adnexal Mass
Women with an adnexal mass (pelvic mass) as confirmed by imaging

Primary Outcome Measures :
  1. To determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the VOCAL test [ Time Frame: 24-48 Months ]

Secondary Outcome Measures :
  1. To evaluate the association of protein and glycoprotein (GP) biomarkers with histological subtypes, stage, treatments and disease free survival (DFS) among woman with ovarian cancer [ Time Frame: 24-48 Months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Per eligibility, individuals must have a known adnexal mass (pelvic mass).
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Adult women who present with a known adnexal mass as described in the study inclusion and exclusion criteria.

Inclusion Criteria:

  • Women age 18 years or older
  • Able to provide a written informed consent and who understand and agree to all study procedures required
  • A newly diagnosed adnexal mass as confirmed by imaging (computed tomography, ultrasonography, or magnetic resonance imaging) prior to enrollment
  • Planned diagnostic procedure or surgery by the subject's physician to remove adnexal masses within 90 days of imaging. (Note that diagnostic procedure typically includes biopsy (needle core or laparoscopic-directed), ascites cytology, pleural effusion cytology or FNA)

Exclusion Criteria:

  • Had/Has a diagnosis of invasive malignancy (exception: non-melanoma skin cancers) in the previous 5 years.
  • Currently receiving or ever received any of the following prior cancer therapies in the previous 5 years. This includes curative surgical resection, local or systemic chemotherapy, targeted therapy, immunotherapy including cancer vaccines, hormone therapy, and/or radiation therapy.
  • Pregnancy
  • Current febrile illness
  • Acute exacerbation or flare of an inflammatory condition requiring escalation in therapy
  • Recipient of organ transplant
  • Poor health status or unfit to tolerate blood draw

In addition, this study will include a small subgroup of women with a newly diagnosed clinically benign adnexal mass(es) for whom surgery is not planned as determined by the treating physician. This subgroup will follow the same exclusion criteria as listed above.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03837327

Layout table for location contacts
Contact: Klaus Lindpaintner, MD 1-888-706-1670
Contact: Kaitlynn Moser 1-888-706-1670

Show Show 24 study locations
Sponsors and Collaborators
Venn Biosciences Corporation
Layout table for investigator information
Study Chair: Klaus Lindpaintner, MD Venn Biosciences Corporation
Layout table for additonal information
Responsible Party: Venn Biosciences Corporation Identifier: NCT03837327    
Other Study ID Numbers: OVACA-001
First Posted: February 12, 2019    Key Record Dates
Last Update Posted: June 28, 2022
Last Verified: June 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Venn Biosciences Corporation:
Ovarian Cancer
Liquid Biopsy
Mass Spectrometry
Adnexal Mass/ Pelvic Mass
Venn Biosciences
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Carcinoma, Ovarian Epithelial
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Genital Diseases
Endocrine System Diseases
Gonadal Disorders